{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T10:13:51Z","timestamp":1784542431411,"version":"3.55.0"},"reference-count":12,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T00:00:00Z","timestamp":1713312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:p>High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation is the standard of care for eligible patients with newly diagnosed multiple myeloma leading to prolonged progression free and overall survival. Successful engraftment following hematopoietic stem cell infusion requires adequate stem cell doses. Current mobilization regimens include granulocyte colony-stimulating factor (G-CSF) with or without plerixafor. Motixafortide is a recently approved agent that can be used in combination with G-CSF for mobilization. In the absence of any head-to-head trials comparing the two products, this article aims to outline the similarities and differences of these two agents. Though moxitafortide has a more favorable pharmacokinetic profile in comparison to plerixafor, in clinical trials, the agents demonstrated similar efficacy. In addition, the use of motixafortide in clinical practice may be limited by product cost as well as administration and monitoring requirements.<\/jats:p>","DOI":"10.1177\/10781552241247472","type":"journal-article","created":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T04:17:39Z","timestamp":1713327459000},"page":"1073-1077","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["A comparative review of Aphexda and Mozobil for mobilization prior to stem cell collection"],"prefix":"10.1177","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-1706-0759","authenticated-orcid":false,"given":"Lauren","family":"Dietz","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Medical University of South Carolina Health, Charleston, SC, US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Marini","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Medical University of South Carolina Health, Charleston, SC, US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza","family":"Hashmi","sequence":"additional","affiliation":[{"name":"Division of Hematology Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY, US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"McGann","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Medical University of South Carolina Health, Charleston, SC, US"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,4,17]]},"reference":[{"key":"bibr1-10781552241247472","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611750"},{"key":"bibr2-10781552241247472","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204925"},{"key":"bibr3-10781552241247472","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.10.013"},{"key":"bibr4-10781552241247472","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05170-0"},{"key":"bibr5-10781552241247472","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02273-z"},{"key":"bibr6-10781552241247472","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-08-174946"},{"key":"bibr7-10781552241247472","unstructured":"Genzyme Corporation. Mozobil (plerixafor) [package insert]. U.S. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/022311s001lbl.pdf. Revised April 2010. Accessed November 2023."},{"key":"bibr8-10781552241247472","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.09.005"},{"key":"bibr9-10781552241247472","first-page":"1","volume":"11","author":"Rahi CE","year":"2018","journal-title":"Clin Med Insights Blood Disord"},{"key":"bibr10-10781552241247472","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2017.103"},{"key":"bibr11-10781552241247472","unstructured":"BioLineRx Ltd TM. Aphexda (motixafortide) [package insert]. U.S. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/217159s000lbl.pdf. Revised September 2023. Accessed November 2023."},{"key":"bibr12-10781552241247472","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.02.013"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552241247472","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552241247472","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552241247472","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:29:46Z","timestamp":1777688986000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552241247472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,17]]},"references-count":12,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.1177\/10781552241247472"],"URL":"https:\/\/doi.org\/10.1177\/10781552241247472","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,17]]}}}